JP7295799B2 - 抗原特異的抗体を選択的に枯渇させるための融合タンパク質 - Google Patents

抗原特異的抗体を選択的に枯渇させるための融合タンパク質 Download PDF

Info

Publication number
JP7295799B2
JP7295799B2 JP2019529975A JP2019529975A JP7295799B2 JP 7295799 B2 JP7295799 B2 JP 7295799B2 JP 2019529975 A JP2019529975 A JP 2019529975A JP 2019529975 A JP2019529975 A JP 2019529975A JP 7295799 B2 JP7295799 B2 JP 7295799B2
Authority
JP
Japan
Prior art keywords
seq
seldeg
antigen
fragment
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019529975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500885A (ja
JP2020500885A5 (enExample
Inventor
オーバー，エリザベス・サリー・ウォード
デバナボイナ，ベンカタ・シバ・チャラン
オーバー，ライムンド・ヨハネス
Original Assignee
ザ テキサス エー アンド エム ユニバーシティー システム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ テキサス エー アンド エム ユニバーシティー システム filed Critical ザ テキサス エー アンド エム ユニバーシティー システム
Publication of JP2020500885A publication Critical patent/JP2020500885A/ja
Publication of JP2020500885A5 publication Critical patent/JP2020500885A5/ja
Priority to JP2023095266A priority Critical patent/JP7832913B2/ja
Application granted granted Critical
Publication of JP7295799B2 publication Critical patent/JP7295799B2/ja
Priority to JP2025094049A priority patent/JP2025131743A/ja
Priority to JP2026035146A priority patent/JP2026097946A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2019529975A 2016-12-02 2017-12-01 抗原特異的抗体を選択的に枯渇させるための融合タンパク質 Active JP7295799B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2023095266A JP7832913B2 (ja) 2016-12-02 2023-06-09 抗原特異的抗体を選択的に枯渇させるための融合タンパク質
JP2025094049A JP2025131743A (ja) 2016-12-02 2025-06-05 抗原特異的抗体を選択的に枯渇させるための融合タンパク質
JP2026035146A JP2026097946A (ja) 2016-12-02 2026-03-05 抗原特異的抗体を選択的に枯渇させるための融合タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662429367P 2016-12-02 2016-12-02
US62/429,367 2016-12-02
PCT/US2017/064186 WO2018102668A1 (en) 2016-12-02 2017-12-01 Fusion proteins for selectively depleting antigen-specific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023095266A Division JP7832913B2 (ja) 2016-12-02 2023-06-09 抗原特異的抗体を選択的に枯渇させるための融合タンパク質

Publications (3)

Publication Number Publication Date
JP2020500885A JP2020500885A (ja) 2020-01-16
JP2020500885A5 JP2020500885A5 (enExample) 2021-01-21
JP7295799B2 true JP7295799B2 (ja) 2023-06-21

Family

ID=62242041

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019529975A Active JP7295799B2 (ja) 2016-12-02 2017-12-01 抗原特異的抗体を選択的に枯渇させるための融合タンパク質
JP2023095266A Active JP7832913B2 (ja) 2016-12-02 2023-06-09 抗原特異的抗体を選択的に枯渇させるための融合タンパク質
JP2025094049A Pending JP2025131743A (ja) 2016-12-02 2025-06-05 抗原特異的抗体を選択的に枯渇させるための融合タンパク質
JP2026035146A Pending JP2026097946A (ja) 2016-12-02 2026-03-05 抗原特異的抗体を選択的に枯渇させるための融合タンパク質

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2023095266A Active JP7832913B2 (ja) 2016-12-02 2023-06-09 抗原特異的抗体を選択的に枯渇させるための融合タンパク質
JP2025094049A Pending JP2025131743A (ja) 2016-12-02 2025-06-05 抗原特異的抗体を選択的に枯渇させるための融合タンパク質
JP2026035146A Pending JP2026097946A (ja) 2016-12-02 2026-03-05 抗原特異的抗体を選択的に枯渇させるための融合タンパク質

Country Status (7)

Country Link
US (2) US11459396B2 (enExample)
EP (1) EP3548073A4 (enExample)
JP (4) JP7295799B2 (enExample)
CN (1) CN110799210A (enExample)
AU (2) AU2017366674B2 (enExample)
CA (1) CA3045797A1 (enExample)
WO (1) WO2018102668A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020518240A (ja) * 2017-01-17 2020-06-25 ザ テキサス エー アンド エム ユニバーシティー システム 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート
AU2018318440A1 (en) 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
EP3715375A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of pre-eclampsia
EP3715376A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of myasthenia gravis
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
TWI922495B (zh) 2020-09-23 2026-04-21 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
WO2022063879A1 (en) 2020-09-23 2022-03-31 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
KR20230074775A (ko) 2020-09-23 2023-05-31 아블레비아 바이오테크 게엠베하 바이러스 벡터의 효능 증가를 위한 화합물
WO2022063887A1 (en) 2020-09-23 2022-03-31 Ablevia Biotech Gmbh Compound for increasing the efficacy of factor viii replacement therapy
EP4217402A1 (en) 2020-09-23 2023-08-02 Ablevia biotech GmbH Compound for the prevention or treatment of autoantibody-mediated conditions
CN116710143A (zh) 2020-09-24 2023-09-05 艾柏力维亚生技有限公司 用于预防或治疗重症肌无力的化合物
WO2023180502A1 (en) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Compound for increasing efficacy of oncolytic viruses
CN119013290A (zh) 2022-04-13 2024-11-22 Ose免疫疗法公司 用于选择性清除抗体的新型分子
AU2023367846A1 (en) * 2022-10-26 2025-05-01 Amgen Inc. Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases
CN120624489B (zh) * 2025-08-18 2025-12-02 天津医科大学总医院 一种嵌合aqp4抗体受体、caar-t细胞及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012503007A (ja) 2008-09-17 2012-02-02 ゼンコア インコーポレイテッド ＩｇＥ媒介性疾患を治療するための新規組成物および方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7332168B2 (en) 2000-08-22 2008-02-19 Micromet Ag Composition for the elimination of autoreactive B-cells
AU2002236499A1 (en) 2000-11-30 2002-06-11 Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
EP3415528B1 (en) 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
WO2012150319A1 (en) * 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
CN106103476B (zh) * 2013-12-24 2020-11-27 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
US20160060358A1 (en) 2014-08-28 2016-03-03 California Institute Of Technology Induction of antigen-specific tolerance
US20170334962A1 (en) * 2016-05-19 2017-11-23 Texas A&M University System FcRn-TARGETED ANTIGEN FUSION PROTEINS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012503007A (ja) 2008-09-17 2012-02-02 ゼンコア インコーポレイテッド ＩｇＥ媒介性疾患を治療するための新規組成物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The International Journal of BiologicalMarkers, 2004, Vol.19, No.3, p.213-220

Also Published As

Publication number Publication date
AU2025202131A1 (en) 2025-04-10
AU2017366674B2 (en) 2025-01-02
JP2020500885A (ja) 2020-01-16
JP2026097946A (ja) 2026-06-16
CN110799210A (zh) 2020-02-14
EP3548073A4 (en) 2020-07-22
US20200031948A1 (en) 2020-01-30
JP2023113894A (ja) 2023-08-16
JP7832913B2 (ja) 2026-03-18
CA3045797A1 (en) 2018-06-07
JP2025131743A (ja) 2025-09-09
US20230087965A1 (en) 2023-03-23
US11459396B2 (en) 2022-10-04
AU2017366674A1 (en) 2019-06-20
EP3548073A1 (en) 2019-10-09
WO2018102668A1 (en) 2018-06-07
US12404339B2 (en) 2025-09-02

Similar Documents

Publication Publication Date Title
JP7832913B2 (ja) 抗原特異的抗体を選択的に枯渇させるための融合タンパク質
CN109715663B (zh) 结合生长抑素受体2的异源二聚抗体
US20230390413A1 (en) Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells
JP7065766B2 (ja) 改変ｊ鎖を有する結合分子
US20160009824A1 (en) Tetravalent bispecific antibodies
TW202400642A (zh) 抗ＣＤ２８ｘ抗ＰＳＭＡ抗體
JP2026048845A (ja) メソテリン結合タンパク質及びその使用
KR20230141817A (ko) 이중특이 항체
TW202525853A (zh) 抗ｃｄ２０ｘ抗ｃｄ２８組合療法
CN119698294A (zh) 结合γ-δT细胞受体的变体抗体
KR20240052030A (ko) 높은 열 안정성 및 감쇠된 효과기 기능을 갖는 fc 변이체
US20260035435A1 (en) Approaches for the selective depletion of pla2r-specific antibodies
WO2026064598A1 (en) Approaches for the selective depletion of adamts13-specific antibodies
AU2023293720A1 (en) Compositions comprising antibodies that bind gamma-delta t cell receptors
CA3237038A1 (en) Compositions and methods for the modulation of beta chain-mediated immunity
HK40007765A (en) Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230310

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230609

R150 Certificate of patent or registration of utility model

Ref document number: 7295799

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250